By Marie Rosenthal
Saying the benefits no longer outweigh the potential risks, the FDA revoked the emergency use authorization (EUA) for hydroxychloroquine sulfate (HCQ) and chloroquine phosphate (CQ) to treat COVID-19.
The EUA allowed hydroxychloroquine and chloroquine to be donated to the Strategic National Stockpile to be used to treat certain hospitalized patients with COVID-19 when a clinical trial was unavailable, or participation in a clinical trial was not feasible. The agency determined